Gary D. Tollefson

15.8k total citations · 5 hit papers
163 papers, 12.3k citations indexed

About

Gary D. Tollefson is a scholar working on Psychiatry and Mental health, Pharmacology and Experimental and Cognitive Psychology. According to data from OpenAlex, Gary D. Tollefson has authored 163 papers receiving a total of 12.3k indexed citations (citations by other indexed papers that have themselves been cited), including 107 papers in Psychiatry and Mental health, 66 papers in Pharmacology and 29 papers in Experimental and Cognitive Psychology. Recurrent topics in Gary D. Tollefson's work include Schizophrenia research and treatment (71 papers), Treatment of Major Depression (58 papers) and Bipolar Disorder and Treatment (44 papers). Gary D. Tollefson is often cited by papers focused on Schizophrenia research and treatment (71 papers), Treatment of Major Depression (58 papers) and Bipolar Disorder and Treatment (44 papers). Gary D. Tollefson collaborates with scholars based in United States, Canada and Netherlands. Gary D. Tollefson's co-authors include Charles M. Beasley, T.M. Sanger, S.H. Hamilton, Mauricio Tohen, Pierre V. Trân, Bruce J. Kinon, J. A. Gilmore, Bruce R. Basson, P. Tran and Scott W. Andersen and has published in prestigious journals such as American Journal of Psychiatry, The Journal of Clinical Endocrinology & Metabolism and Biological Psychiatry.

In The Last Decade

Gary D. Tollefson

162 papers receiving 11.6k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

1997 693 citations Gary D. Tollefson, Charles M. Beasley et al. American Journal of Psychiatry profile →
Olanzapine versus Placebo and Haloperidol

1996 643 citations Charles M. Beasley, Gary D. Tollefson et al. profile →
Efficacy of Olanzapine and Olanzapine-Fluoxetine Combination in the Treatment of Bipolar I Depression

2003 622 citations Mauricio Tohen, Franca Centorrino et al. profile →
Double-Blind Comparison of Olanzapine Versus Risperidone in the Treatment of Schizophrenia and Other Psychotic Disorders

1997 567 citations Pierre V. Trân, S.H. Hamilton et al. Journal of Clinical Psychopharmacology profile →
Effects of Xanomeline, a Selective Muscarinic Receptor Agonist, on Cognitive Function and Behavioral Symptoms in Alzheimer Disease

1997 528 citations Gary D. Tollefson, Frank P. Bymaster et al. profile →

Peers

Countries citing papers authored by Gary D. Tollefson

Since Specialization

Citations

This map shows the geographic impact of Gary D. Tollefson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary D. Tollefson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary D. Tollefson more than expected).

Fields of papers citing papers by Gary D. Tollefson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary D. Tollefson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary D. Tollefson. The network helps show where Gary D. Tollefson may publish in the future.

Co-authorship network of co-authors of Gary D. Tollefson

This figure shows the co-authorship network connecting the top 25 collaborators of Gary D. Tollefson. A scholar is included among the top collaborators of Gary D. Tollefson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gary D. Tollefson. Gary D. Tollefson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The association between food cravings and consumption of specific foods in a laboratory taste test 2008 ·Appetite ·Corby K. Martin, Patrick M. O’Neil, Gary D. Tollefson, Frank L. Greenway, Marney A. White	75
2	Onset of antidepressant effect of olanzapine and olanzapine/fluoxetine combination in bipolar depression 2007 ·Bipolar Disorders ·Sanjay Dubé, Gary D. Tollefson, Michael E. Thase, Susan D. Briggs, Luann E. Van Campen, Michael Case, Mauricio Tohen	25
3	Ecological Studies of Antidepressant Treatment and Suicidal Risks 2007 ·Harvard Review of Psychiatry ·Ross J. Baldessarini, Leonardo Tondo, Indiana Strombom, (unknown), Jan Fawcett, Julio Licínio, María A. Oquendo, Gary D. Tollefson, Robert J. Valuck, Mauricio Tohen	57
4	Olanzapine/Fluoxetine Combination for Treatment-Resistant Depression 2005 ·The Journal of Clinical Psychiatry ·Richard C. Shelton, Douglas J. Williamson, S. Corya, T.M. Sanger, Luann E. Van Campen, Michael Case, Susan D. Briggs, Gary D. Tollefson	130
5	Comparative Efficacy and Safety of Atypical and Conventional Antipsychotic Drugs in First-Episode Psychosis: A Randomized, Double-Blind Trial of Olanzapine Versus Haloperidol 2003 ·American Journal of Psychiatry ·Jeffrey A. Lieberman, Gary D. Tollefson, Mauricio Tohen, Alan I. Green, Raquel E. Gur, René S. Kahn, Joseph P. McEvoy, Diana O. Perkins, Tonmoy Sharma, Robert B. Zipursky, (unknown), Robert M. Hamer, (unknown)	322
6	Acute Dysphoric Mania: Treatment Response to Olanzapine Versus Placebo 2003 ·Journal of Clinical Psychopharmacology ·Robert W. Baker, Mauricio Tohen, Jan Fawcett, Richard C. Risser, Leslie M. Schuh, Eileen Brown, Virginia L. Stauffer, Lixin Shao, Gary D. Tollefson	50
7	Assessing and interpreting treatment effects in longitudinal clinical trials with missing data 2003 ·Biological Psychiatry ·Craig Mallinckrodt, T.M. Sanger, Sanjay Dubé, David J. DeBrota, Geert Molenberghs, Raymond J. Carroll, William Z. Potter, Gary D. Tollefson	188
8	Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double‐blind controlled trial 2003 ·International Journal of Geriatric Psychiatry ·John Kennedy, Dilip V. Jeste, Christopher Kaiser, S. Golshan, Gerald A. Maguire, Gary D. Tollefson, T.M. Sanger, Frank P. Bymaster, Bruce J. Kinon, Martín Dossenbach, J. A. Gilmore, Alan Breier	30
9	Skating to where the puck is going to be: a plan for clinical trials and translation research in mood disorders 2002 ·Biological Psychiatry ·Ellen Frank, A. John Rush, Mary C. Blehar, Susan M. Essock, William A. Hargreaves, Michael Hogan, Robin B. Jarrett, Robert L. Johnson, Wayne Katon, Phillip W. Lavori, James McNulty, George Niederehe, Neal D. Ryan, Gail W. Stuart, Stephen B. Thomas, Gary D. Tollefson, Benedetto Vitiello	13
10	Current issues in the psychopharmacology of schizophrenia 2001 ·Lippincott Williams & Wilkins eBooks ·Alan Breier, P. Tran, John M. Herrera, Gary D. Tollefson, Frank P. Bymaster	31
11	Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex 1999 ·Acta Neurobiologiae Experimentalis ·Kenneth W. Perry, Frank P. Bymaster, Gary D. Tollefson, (unknown)	3
12	Continuing treatment of panic disorder after acute response: randomised, placebo-controlled trial with fluoxetine 1999 ·The British Journal of Psychiatry ·David Michelson, Mark H. Pollack, R. Bruce Lydiard, Roy Tamura, R. Tepner, Gary D. Tollefson, (unknown)	37
13	Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol 1999 ·The British Journal of Psychiatry ·Charles M. Beasley, Mary Anne Dellva, Roy Tamura, Hal Morgenstern, William M. Glazer, (unknown), Gary D. Tollefson	173
14	Olanzapine Versus Placebo in the Treatment of Acute Mania 1999 ·American Journal of Psychiatry ·Mauricio Tohen, T.M. Sanger, Susan L. McElroy, Gary D. Tollefson, K. N. Roy Chengappa, David G. Daniel, Frederick Petty, Franca Centorrino, (unknown), Starr L. Grundy, (unknown), T. Jacobs, S.R. David, V. Toma, (unknown)	443
15	The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone 1999 ·Biological Psychiatry ·Gary D. Tollefson, Scott W. Andersen, Pierre V. Trân	68
16	Outcome Assessment and Clinical Improvement in Panic Disorder: Evidence From a Randomized Controlled Trial of Fluoxetine and Placebo 1998 ·American Journal of Psychiatry ·David Michelson, R. Bruce Lydiard, Mark H. Pollack, Roy Tamura, S. Hoog, R. Tepner, Mark A. Demitrack, Gary D. Tollefson, (unknown)	89
17	Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial 1996 ·Psychopharmacology ·Charles M. Beasley, T.M. Sanger, W. Satterlee, Gary D. Tollefson, P. Tran, S.H. Hamilton	320
18	Course of psychomotor agitation during pharmacotherapy of depression: Analysis from double-blind controlled trials with fluoxetine 1996 ·Depression and Anxiety ·Gary D. Tollefson, (unknown)	8
19	How long to onset of antidepressant action 1994 ·International Clinical Psychopharmacology ·Gary D. Tollefson, (unknown)	49
20	A double-blind trial of fluoxetine, 20 mg, and placebo in out-patients with DSM-III-R major depression and melancholia 1993 ·International Clinical Psychopharmacology ·John H. Heiligenstein, Gary D. Tollefson, Douglas E. Faries	33

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact